Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Metrics to compare | MIST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMISTPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.3x | −0.7x | −0.5x | |
PEG Ratio | −0.09 | −0.01 | 0.00 | |
Price / Book | −27.8x | 0.8x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.1x | |
Upside (Analyst Target) | 56.3% | 128.3% | 45.7% | |
Fair Value Upside | Unlock | 18.6% | 5.7% | Unlock |